FDA Approves HYDROCODONE BITARTRATE AND ACETAMINOPHEN — SpecGx LLC
SpecGx LLC secured FDA approval for filing ANDA040405, gaining market access for generic HYDROCODONE BITARTRATE AND ACETAMINOPHEN. The entry of this generic alternative is expected to intensify market competition and erode pricing power for branded formulations in the opioid analgesic sector.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day